P/E ratio for Actinium Pharmaceuticals (ATNM)
P/E ratio as of May 2024 (TTM): -5.32
According to Actinium Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.32418. At the end of 2022 the company had a P/E ratio of -7.77.
P/E ratio history for Actinium Pharmaceuticals from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.77 | 55.22% |
| 2021 | -5.01 | 36.12% |
| 2020 | -3.68 | 153.67% |
| 2019 | -1.45 | -17.55% |
| 2018 | -1.76 | 8.62% |
| 2017 | -1.62 | -7.46% |
| 2016 | -1.75 | -70.2% |
| 2015 | -5.87 | -10.26% |
| 2014 | -6.54 | -47.78% |
| 2013 | -12.5 | 3287.38% |
| 2012 | -0.3700 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Genocea Biosciences
GNCA | -0.0002 | -100.00% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | -15.2 | 186.14% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 99.0 | -1,958.54% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.